Optimal Anti-Thrombotic Therapy After TAVR – Updates and Controversies

Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of patients with any cardiovascular disease to include devices, drugs, and digital health care products listed below:

• Consultant Fee/Honoraria/Speaker's Bureau (Personal) - Amgen; Arena; Daiichi-Sankyo/Elil Lilly and Company; Sanofi-Aventis; Terumo Medical Corporation
• Consultant Fee/Honoraria/Speaker's Bureau (Institutional) - Medtronic